Jing Zhao

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

Martin Markowitz, Javier O Morales-Ramirez, Bach‐Yen Nguyen et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 366 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 228 citations

Life Sciences, Pharmacology, Pharmacotherapy +17

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · Journal of Clinical Oncology · 2020 · 185 citations

Medicine, Oncology, Pharmacology +17